A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

The FDA on Tuesday signed off on Supernus Pharmaceuticals’ apomorphine hydrochloride injection—to be marketed under the brand ...

The GLP-1 drug, exenatide, has no positive impact on the movement, symptoms or brain imaging of people with Parkinson's ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

Newronika, the developer of groundbreaking adaptive deep brain stimulation technology, is proud to announce the receipt of an ...

A County Durham man is one of the first patients in England to benefit from a new Parkinson's disease treatment.

Michael Katz and Richard Balanson have many things in common. They both live in New South Wales, have spent much of their ...

Traditional deep brain stimulation surgery can take up to 10 hours to complete, with the patient wide awake. This robotic ...

The discovery and development of GLP-1 receptor agonists for type 2 diabetes and obesity is a bench-to-bedside success story.1 Multiple GLP-1 receptor agonists are now in clinical use, such as ...